Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-κB pathway in HT-29 cells

PurposePseudolaric acid B (PAB) is a diterpene acid isolated from the root and trunk bark of Pseudolaric kaempferi Gordon. Previous work has found that PAB has anti-inflammatory and anti-tumor effects in xenograft models of human hepatocellular carcinoma. The aim of this study is to evaluate the correlation between anti-cancer and anti-inflammatory effects of PAB and its molecular mechanisms on HT-29 cells.MethodsProduction of prostaglandin E2 (PGE2) in HT-29 cells was evaluated by ELISA. mRNA of cyclooxygenase-2 (COX-2) was analyzed by RT-PCR assay. High-content screening (HCS) method was adopted to detect the cytokine mixture (CM)-induced transcription activity of NF-κB and STAT3. Western blotting was used to evaluate the protein expression levels of inflammatory mediators induced by CM. After treatment with PAB in various concentrations, the inhibition rate of cell proliferation was measured with sulforhodamine B assays. For the in vivo studies, tumor-bearing models xenografted with HT-29 cells were developed in nude mice, and following oral administration with PAB, tumor inhibition rate was calculated.ResultsPAB inhibited the PGE2 production in HT-29 cells significantly (P < 0.05) with similar results detected at the COX-2 mRNA level. Furthermore, PAB suppressed the COX-2 protein expression and significant nuclear translocation of NF-κB and STAT3 induced by CM, which correlated with a concomitant degradation of I-κB and a decrease in constitutive STAT3 phosphorylation (P < 0.05). Moreover, various concentrations of PAB inhibited the proliferation of HT-29 cells in a dose- and time-dependent manner. In vivo, after treatment with PAB for 17 days, the tumor weight of the 50 and 100 mg/kg treated groups was 0.62 ± 0.15 and 0.54 ± 0.06 g, respectively. When compared to the control group (0.82 ± 0.16 g), the inhibition rate of tumor weight was 24.2% at 50 mg/kg (P < 0.05) and 34.7% at 100 mg/kg (P < 0.001).ConclusionsPAB shows potential anti-cancer activity in HT-29 cells, and its molecular mechanisms are related to the anti-inflammatory action.

[1]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[2]  Nadir Arber,et al.  Inflammation and colorectal cancer. , 2009, Current opinion in pharmacology.

[3]  T. Ikejima,et al.  Protein tyrosine kinase, JNK, and ERK involvement in pseudolaric acid B-induced apoptosis of human breast cancer MCF-7 cells , 2008, Acta Pharmacologica Sinica.

[4]  W. Ho,et al.  Herbal diterpenoids induce growth arrest and apoptosis in colon cancer cells with increased expression of the nonsteroidal anti-inflammatory drug-activated gene. , 2007, European journal of pharmacology.

[5]  Tong Wu,et al.  Cyclooxygenase-2 in hepatocellular carcinoma. , 2006, Cancer treatment reviews.

[6]  K. Wafford,et al.  New directions in kinetic high information content assays. , 2006, Drug discovery today.

[7]  O. Ogunwobi,et al.  Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways , 2006, Regulatory Peptides.

[8]  Hua Yu,et al.  Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. , 2009, Cancer cell.

[9]  D. Fuchs,et al.  The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1 , 2007, Oncogene.

[10]  R. Jorissen,et al.  Epidermal growth factor receptor , 2003 .

[11]  E. El-Omar,et al.  Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[12]  D. Dixon.  Dysregulated post-transcriptional control of COX-2 gene expression in cancer. , 2004, Current pharmaceutical design.

[13]  R. DuBois,et al.  Pro-inflammatory prostaglandins and progression of colorectal cancer. , 2008, Cancer letters.

[14]  Michael Karin,et al.  Inflammation and colon cancer. , 2010, Gastroenterology.

[15]  G. Hou,et al.  mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. , 2010, Cancer letters.

[16]  Liang Liu,et al.  Pseudolaric acid B suppresses T lymphocyte activation through inhibition of NF‐κB signaling pathway and p38 phosphorylation , 2009, Journal of cellular biochemistry.

[17]  S. Shiff,et al.  Cyclooxygenase inhibitors: drugs for cancer prevention. , 2003, Current opinion in pharmacology.

[18]  T. Ikejima,et al.  Pseudolaric acid B induces apoptosis, senescence, and mitotic arrest in human breast cancer MCF-7 , 2007, Acta Pharmacologica Sinica.

[19]  Sheng-Chieh Hsu,et al.  Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. , 2005, Cancer cell.

[20]  M. Karin,et al.  Autocrine IL-6 signaling: a key event in tumorigenesis? , 2008, Cancer cell.

[21]  P. Loehrer.  Celecoxib for the Prevention of Colorectal Adenomatous Polyps , 2008 .

[22]  M. Karin,et al.  The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. , 2008, Trends in molecular medicine.

[23]  Masao Tanaka,et al.  Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-κB activation , 2000, Oncogene.

[24]  J. Jeon,et al.  Ethyl pyruvate has an anti-inflammatory effect by inhibiting ROS-dependent STAT signaling in activated microglia. , 2008, Free radical biology & medicine.

[25]  L. Chow,et al.  Pseudolaric Acid B, a Novel Microtubule-Destabilizing Agent That Circumvents Multidrug Resistance Phenotype and Exhibits Antitumor Activity In vivo , 2005, Clinical Cancer Research.

[26]  P. Tak,et al.  NF-kappaB: a key role in inflammatory diseases. , 2001, The Journal of clinical investigation.

[27]  G. K. Khurana Hershey,et al.  Turning off signal transducer and activator of transcription (STAT): the negative regulation of STAT signaling. , 2004, The Journal of allergy and clinical immunology.

[28]  Wenzheng Zhang,et al.  Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. , 2002, The Biochemical journal.

[29]  Michael J Thun,et al.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.

[30]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[31]  M. Karin,et al.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.

[32]  Warren S. Alexander,et al.  Suppressors of cytokine signalling (SOCS) in the immune system , 2002, Nature Reviews Immunology.

[33]  T. Ikejima,et al.  Involvement of JNK-initiated p53 accumulation and phosphorylation of p53 in pseudolaric acid B induced cell death , 2006, Experimental & Molecular Medicine.

[34]  K. Lee,et al.  The cytotoxic principles of Pseudolarix kaempferi: pseudolaric acid-A and -B and related derivatives. , 1990, Planta medica.

[35]  Ling-ling Jiang,et al.  Induction of G2/M arrest by pseudolaric acid B is mediated by activation of the ATM signaling pathway , 2009, Acta Pharmacologica Sinica.

[36]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[37]  Yi Chen,et al.  Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect. , 2004, European journal of pharmacology.

[38]  Jian Ding,et al.  Pseudolarix Acid B, a New Tubulin-Binding Agent, Inhibits Angiogenesis by Interacting with a Novel Binding Site on Tubulin , 2006, Molecular Pharmacology.

[39]  P. Malfertheiner,et al.  Oxidative stress in ulcerative colitis-associated carcinogenesis. , 2008, Pathology, research and practice.

[40]  Antony W Burgess,et al.  Epidermal growth factor receptor: mechanisms of activation and signalling. , 2003, Experimental cell research.

[41]  Ming Liu,et al.  Cytokines and their relationship to the symptoms and outcome of cancer , 2010 .

[42]  S. Grösch,et al.  Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. , 2004, Biochemical pharmacology.